Overview

* Surrozen ( SRZN ) Q3 net loss widens significantly year-over-year, with no collaboration revenue

* Operating expenses increased due to higher R&D costs in ophthalmology programs

* Company strengthens leadership with new CFO, Andrew Maleki, focusing on growth

Outlook

* Company did not provide specific financial guidance for the current or future periods

Result Drivers

* INCREASED R&D EXPENSES - R&D expenses rose due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$8.36

Q3 Net -$71.64

Income mln

Q3 $11.87

Operatin mln

g

Expenses

Q3 -$10.89

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Surrozen Inc ( SRZN ) is $37.00, about 66.2% above its November 6 closing price of $12.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)